Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | FGF23 | Q9GZV9 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RRM1 | P23921 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468002 | 1.00 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B | |
| SCHEMBL11878472 | 0.78 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B | |
| SCHEMBL2161965 | 0.73 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B | |
| SCHEMBL762978 | 0.73 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B | |
| SCHEMBL2161969 | 0.73 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B | |
| SCHEMBL16224318 | 0.72 | L3MBTL1 (0.53) | NPC1RAB9ASMN1; SMN2ALDH1A1RRM1 | |
| SCHEMBL11743247 | 0.72 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B | |
| SCHEMBL2608307 | 0.72 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL28407082 | 0.71 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL17560873 | 0.71 | L3MBTL1 (0.51) | NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6413962-B1 | ANESTHESIA AND TEMPERATURES REDUCTION; ALPHA-ADRENOCEPTOR AGONIST; RESTORATIVE TO CENTRAL NERVOUS SYSTEM, ESPECIALLY MOTOR AND SENSORY FUNCTIONAL LOSSES FROM TRAMATIC SPINAL CORD INJURIES; ANTISPASTICS; NONSEDATIVE; SIDE EFFECT REDUCTION | NAFTCHI N ERIC (US) | 2002-07-02 | — | — | US | claimed |
| US-20070082918-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS AND COMPOUNDS WITH MULTIPLE ACTIVITIES | NAFTCHI N E | 2007-04-12 | — | — | US | disclosed |
| US-7109329-B2 | Neurologically active compounds and compounds with multiple activities | NAFTCHI N ERIC | 2006-09-19 | — | — | US | disclosed |
| US-20040092536-A1 | Neurologically active compounds and compounds with multiple activities | NAFTCHI N ERIC (US) | 2004-05-13 | — | — | US | disclosed |
| US-6413962-B1 | ANESTHESIA AND TEMPERATURES REDUCTION; ALPHA-ADRENOCEPTOR AGONIST; RESTORATIVE TO CENTRAL NERVOUS SYSTEM, ESPECIALLY MOTOR AND SENSORY FUNCTIONAL LOSSES FROM TRAMATIC SPINAL CORD INJURIES; ANTISPASTICS; NONSEDATIVE; SIDE EFFECT REDUCTION | NAFTCHI N ERIC (US) | 2002-07-02 | — | — | US | disclosed |
| US-5958933-A | HAVING A GUANIDINO GROUP ALIPHATICALLY LINKED TO A XANTHINE GROUP, ADRENERGIC STIMULANTS | NAFTCHI N ERIC (US) | 1999-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092536-A1 | Neurologically active compounds and compounds with multiple activities | ACHE, GRIN2A, GRIK2 | NPC1 942/4885RAB9A 135/4885SMN1; SMN2 22/4885 |
| US-20070082918-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS AND COMPOUNDS WITH MULTIPLE ACTIVITIES | ADRB2, ADRB1, CHRNA7 | NPC1 372/4885RAB9A 1141/4885SMN1; SMN2 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.